Drug delivery agent that acts as a drug for synergistic activity

Drug delivery vehicles increase cell permeability of their cargo, but otherwise are expected to be inert. In developing a potential strategy to treat myotonic dystrophy type 1, we developed a delivery vehicle that was designed to be a direct acting drug. The oligomeric delivery agent selectively targets the expanded DNA and RNA repeat sequences (d(CTG)<sup>exp</sup> and r(CUG)<sup>exp</sup>) that cause DM1. By forming polyplexes with a locked nucleic acid CAG16 gapmer, that targets r(CUG)<sup>exp</sup>, the polyplex facilitates cellular uptake of the LNA in HeLa cells, DM1 patient myoblasts, and the skeletal muscle of DM1 mice leading to phenotypic improvements in the <i>in vitro</i> DM1 models. Although the <i>in vivo</i> results are mixed, the overall results suggest the potential of a new strategy where both drug and delivery agent actively target a disease pathology.

Authors

Institutions

Publication Details

Journal
iScience
Published
2025-06-13
DOI
https://doi.org/10.1016/j.isci.2025.112890
Citations
1
Primary Topic
Pharmacological Effects of Natural Compounds
Type
article
Field-Weighted Citation Impact
1.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Drug delivery agent that acts as a drug for synergistic activity

Sarah Krueger, Steven C. Zimmerman, Philip A. Kocheril, Ullas V. Chembazhi et al.
1 citations
iScience
Pharmacological Effects of Natural Compounds
1.56
article

Drug delivery agent that acts as a drug for synergistic activity

Sarah Krueger, Steven C. Zimmerman, Philip A. Kocheril, Ullas V. Chembazhi, Yugang Bai, Zachary Dewald, Auinash Kalsotra, Amie N. Lanzendorf, Jie Chen, Ke Li, Dongwook Kim, Junfeng Chen
article en
1 citations

Abstract

Drug delivery vehicles increase cell permeability of their cargo, but otherwise are expected to be inert. In developing a potential strategy to treat myotonic dystrophy type 1, we developed a delivery vehicle that was designed to be a direct acting drug. The oligomeric delivery agent selectively targets the expanded DNA and RNA repeat sequences (d(CTG)<sup>exp</sup> and r(CUG)<sup>exp</sup>) that cause DM1. By forming polyplexes with a locked nucleic acid CAG16 gapmer, that targets r(CUG)<sup>exp</sup>, the polyplex facilitates cellular uptake of the LNA in HeLa cells, DM1 patient myoblasts, and the skeletal muscle of DM1 mice leading to phenotypic improvements in the <i>in vitro</i> DM1 models. Although the <i>in vivo</i> results are mixed, the overall results suggest the potential of a new strategy where both drug and delivery agent actively target a disease pathology.

iScienceVol. 28(8)
Ben-Gurion University of the Negev (IL), University of Illinois Urbana-Champaign (US), Chan Zuckerberg Biohub San Francisco (US), Chan Zuckerberg Biohub Chicago, Mount St. Mary's University (US)
Muscular Dystrophy Association, National Institutes of Health
Openalex Percentile: Top 18%
Pharmacological Effects of Natural Compounds
1.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.